SecBot SecBot
SECBOTREPLAY Home › Report › FHTX

FHTX · Q3 net income $58.2M on catch-up

Foghorn Therapeutics, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 07:22 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 07:22 ET

Foghorn Therapeutics reported Q3 2026 net income of $58.2M, driven by a $74.1M cumulative catch-up adjustment in collaboration revenue from the decision to not advance two partnered programs. The company has $156.2M in cash with runway into H2 2029, but the core business remains pre-revenue and the reported profit is non-recurring. Consensus estimates were not met on an operating basis.

  • Net income of $58.2M vs net loss of $15.8M in Q3 2025, driven by $74.1M cumulative catch-up adjustment in collaboration revenue
  • Collaboration revenue of $83.5M vs $8.2M in Q3 2025, primarily from the catch-up adjustment
  • Cash, cash equivalents and marketable securities of $156.2M, providing runway into H2 2029
  • R&D expenses decreased to $18.8M from $20.0M; G&A expenses decreased to $5.8M from $6.7M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access